# A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

> **NCT05455684** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 513 (actual)

## Conditions studied

- Depressive Disorder, Major
- Anhedonia

## Interventions

- **DRUG:** Aticaprant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05455684
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-22
- **Primary completion:** 2024-09-18
- **Final completion:** 2024-09-18
- **Target enrollment:** 513 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05455684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05455684, "A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05455684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*